Molecular and cellular insights into the role of SND1 in lipid metabolism
Publication date: Available online 21 January 2020Source: Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of LipidsAuthor(s): Hiart Navarro-Imaz, Begoña Ochoa, Itsaso García-Arcos, María José Martínez, Yolanda Chico, Olatz Fresnedo, Yuri RuedaAbstractStaphylococcal nuclease and Tudor domain containing 1 (SND1) is an evolutionarily conserved protein present in eukaryotic cells from protozoa to mammals. SND1 has gained importance because it is overexpressed in aggressive cancer cells and diverse primary tumors. Indeed, it is regarded as a marker of cancer malignity. A broad range of molecular functions and the participation in many cellular processes have been attributed to SND1, mostly related to the regulation of gene expression. An increasing body of evidence points to a relevant relationship between SND1 and lipid metabolism. In this review, we summarize the knowledge about SND1 and its molecular and functional relationship with lipid metabolism. We highlight that SND1 plays a direct role in the regulation of cholesterol metabolism by affecting the activation of sterol response element-binding protein 2 (SREBP2) and we propose that that might have implications in the response of lipid homeostasis to stress situations.
In this study, fluorescence emission spectroscopy and mass spectrometry (MALDI-TOF) were employed to define the putative interaction sites and their accessibility for the biologically important metals of Irving William Series.Key findingsSeveral hotspot residues in the ZAG scaffold involved in these interactions were mapped and their binding affinity score for each metal has been determined. Their binding abilities of these sites and aggregation propensities of ZAG were monitored by fluorescence emission spectroscopy.SignificanceThe prediction of such binding affinity with metals on the active sites and its impact on the c...
Conclusions Preoperative serum TC level is an independent poor prognostic factor for patients with surgically treated RCC, with lower levels associated with worse CSS and PFS. Hence, this parameter may provide additional guidance in the selection of therapeutic strategies to improve prognosis, considering that cholesterol is a broadly applied routine marker in clinical practice.
Conclusions and Implications for Cancer SurvivorsMore than one-third of cancer survivors were statin-eligible but untreated under current guidelines. There is room for improvement to reduce the burden of non-cancer mortality by managing traditional cardiovascular risk factors.
Better understanding needed to stave off overdose deaths, warns HSIB Related items fromOnMedica Withdrawn valsartan meds not linked to short-term cancer risk Too few women take part in many CVD clinical trials Pharmacists could offer high-dose statins direct to patients Cannabinoids not recommended to treat cancer-related pain GPs defend practice on prescribing statins
Women who naturally exhibit lower levels of an enzyme blocked by statins have an estimated 40 per cent lower risk of ovarian cancer, a study by Bristol University found.
In the UK, ovarian cancer is the sixth most common cancer in females*. A new study has found evidence to suggest that statins could lower the risk of women developing ovarian cancer. The research led by the University of Bristol, and funded by Cancer Research UK, is published today [18 February] in JAMA.
Type 2 diabetes (T2D) is a metabolic disorder of insulin resistance — a reduced sensitivity to the action of insulin — which leads to high blood sugar, or hyperglycemia. Approximately 12% of American adults have T2D, and more than one-third of Americans have prediabetes, a precursor to T2D. This is a major public health concern, as T2D dramatically increases risk for heart disease, including heart attacks, atrial fibrillation, and heart failure. The development and progression of T2D is affected by many factors. Some, such as a person’s race/ethnicity, age, and gender cannot be modified. Others, including...
Conclusions: The nanoliposomal PCSK9 vaccine did not adversely affect the growth of melanoma tumour nor the survival of tumour-bearing mice. PMID: 32051723 [PubMed]
The study couldn't prove cause and effect, but it found that statins, taken alone or with metformin, did seem associated with an increase in survival.